TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30463479

Group type: EXPERIMENTAL
Intervention: Very-low-volume HIIT (4-6 work bouts of 60 seconds with 75 seconds of low-intensity recovery)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Very-low-volume HIIT
Number of subjects: 23

Group type: COMPARATOR
Intervention: Low-volume HIIT (8-12 work bouts of 60 seconds with 75 seconds of low-intensity recovery)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 23
Study: 28657793

Group type: EXPERIMENTAL
Intervention: Simvastatin (80 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no simvastatin)
Number of subjects: 0
Study: 25887355

Group type: EXPERIMENTAL
Intervention: Intensive treatment (HbA1c goal < 6%)
Number of subjects: 10251

Group type: COMPARATOR
Intervention: Standard treatment (HbA1c goal 7.0% to 7.9%)
Number of subjects: 10251
Study: 24124951

Group type: EXPERIMENTAL
Intervention: Virtual diabetes educational activity
Number of subjects: 92
Study: 21438849

Group type: EXPERIMENTAL
Intervention: Tipranavir/ritonavir (TPV/r) 500 mg/200 mg
Number of subjects: 12
Study: 19568175

Group type: EXPERIMENTAL
Intervention: HIV counseling and testing offered to women unaware of their HIV status
Number of subjects: 2435

Group type: EXPERIMENTAL
Intervention: Nevirapine (NVP) administration to women who tested positive for HIV
Number of subjects: 2435

Group type: COMPARATOR
Intervention: Inert (calcium) tablet provided to women who tested negative for HIV
Number of subjects: 2435
Study: 17364309

Group type: EXPERIMENTAL
Intervention: Endometrial coagulation
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Endometrial resection
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Endometrial ablation (combined results)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: No further intervention at two-year follow-up
Number of subjects: 120
Study: 15298426

Group type: EXPERIMENTAL
Intervention: Trillium-coated oxygenator
Number of subjects: 0

Group type: COMPARATOR
Intervention: Duraflo II-coated CPB system
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 0
Study: 10993130

Group type: EXPERIMENTAL
Intervention: Reboxetine
Number of subjects: 284

Group type: COMPARATOR
Intervention: Fluoxetine
Number of subjects: 284
Study: 8817259

Group type: EXPERIMENTAL
Intervention: Asynchronous muscle activation during force pulses and steps
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Phasic and tonic EMG activity comparison
Number of subjects: 9
Study: 1585511

Group type: EXPERIMENTAL
Intervention: M-VAC chemotherapy
Number of subjects: 18

Group type: COMPARATOR
Intervention: CisCA chemotherapy
Number of subjects: 18
Study: 2857602

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Labetalol
Number of subjects: 10

Group type: COMPARATOR
Intervention: Isoproterenol
Number of subjects: 10
Study: 28436756

Group type: EXPERIMENTAL
Intervention: Interpersonal Psychotherapy for Adolescents (IPT-A)
Number of subjects: 40
Study: 30192290

Group type: EXPERIMENTAL
Intervention: Hilotherm cooling system
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group without cooling system
Number of subjects: 34
Study: 27704507

Group type: EXPERIMENTAL
Intervention: 10 IU bolus of Oxytocin + 25 IU IVD in 500 ml of serum over 3 hours
Number of subjects: 87

Group type: COMPARATOR
Intervention: 5 IU IVD of Oxytocin + 25 IU in 500 ml serum over 3 hours
Number of subjects: 87
Study: 24667132

Group type: EXPERIMENTAL
Intervention: Se-enriched rice (80 g daily)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Regular rice (80 g daily)
Number of subjects: 20
Study: 22521214

Group type: EXPERIMENTAL
Intervention: Aspirin (ASA) 100/325 mg for 7 days
Number of subjects: 75

Group type: COMPARATOR
Intervention: Baseline
Number of subjects: 75
Study: 20400201

Group type: EXPERIMENTAL
Intervention: Gefitinib 250mg daily
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Gemcitabine (1250mg/m(2) d 1, 8 q 21d)
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Docetaxel (75mg/m(2) d 1 q 21d)
Number of subjects: 127
Study: 19026883

Group type: EXPERIMENTAL
Intervention: EndoREZ with accelerator (A+)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: EndoREZ without accelerator (A-)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Positive control group (Group 5)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Negative control group (Group 6)
Number of subjects: 50
Study: 15876903

Group type: EXPERIMENTAL
Intervention: H. perforatum (900-1500 mg/d)
Number of subjects: 340

Group type: EXPERIMENTAL
Intervention: Sertraline (50-100 mg/d)
Number of subjects: 340

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 340
Study: 12830007

Group type: EXPERIMENTAL
Intervention: Octreotide infusion (50 microg/h)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 11291022

Group type: EXPERIMENTAL
Intervention: Treatment approaches to memory loss, typically using Alzheimer's dementia as the template.
Number of subjects: 0
Study: 8676532

Group type: EXPERIMENTAL
Intervention: Total parenteral nutrition (TPN) continuously throughout the postoperative period
Number of subjects: 14

Group type: COMPARATOR
Intervention: Saline as postoperative fluid therapy
Number of subjects: 14
Study: 1338584

Group type: EXPERIMENTAL
Intervention: Coenzyme Athletic Performance System (CAPS)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo (dicalcium phosphate)
Number of subjects: 11
Study: 31026086

Group type: EXPERIMENTAL
Intervention: Epidural oxycodone 0.1 mg kg‐1 and intravenous saline (EPI-group n = 31)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Intravenous oxycodone 0.1 mg kg‐1 and epidural saline (IV-group n = 29)
Number of subjects: 60
Study: 27111084

Group type: EXPERIMENTAL
Intervention: Rivastigmine patch monotherapy
Number of subjects: 147

Group type: COMPARATOR
Intervention: Combination therapy with memantine
Number of subjects: 147
Study: 26194955

Group type: COMPARATOR
Intervention: Healthy living focused intervention (HL)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Alcohol-focused intervention (AF)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Both interventions (HL and AF)
Number of subjects: 86
Study: 23350886

Group type: EXPERIMENTAL
Intervention: Preoperative nursing visits (two interviews: one day before surgery and one just before entering the operating room)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Preoperative nursing visits
Number of subjects: 100

Group type: COMPARATOR
Intervention: Routine nursing care (control group)
Number of subjects: 100
Study: 20978525

Group type: EXPERIMENTAL
Intervention: Betaine supplementation (4 g/day)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo (mineral water 500 ml/day without betaine)
Number of subjects: 63
Study: 20158691

Group type: EXPERIMENTAL
Intervention: Ibandronate 2 mg every 3 months intravenously for 1 year, along with calcium (1 g/day) and vitamin D3 (800-1000 IE/day)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Control group receiving calcium (1 g/day) and vitamin D3 (800-1000 IE/day)
Number of subjects: 74
Study: 17098464

Group type: EXPERIMENTAL
Intervention: galyfilcon A (silicone hydrogel)
Number of subjects: 24

Group type: COMPARATOR
Intervention: alphafilcon A (conventional hydrogel)
Number of subjects: 24
Study: 16331019

Group type: EXPERIMENTAL
Intervention: Arc-deposited hydroxyapatite-coated cup with alumina-on-alumina bearing surface
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Porous-coated cup with alumina-on-alumina bearing surface
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Porous-coated cup with polyethylene-on-metal bearing surface
Number of subjects: 0

Group type: COMPARATOR
Intervention: Grit-blasted hydroxyapatite-coated cup with polyethylene-on-metal bearing surface
Number of subjects: 0
Study: 11932878

Group type: EXPERIMENTAL
Intervention: Avocado/Soybean Unsaponifiables (ASU)
Number of subjects: 163

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 163
Study: 9797114

Group type: EXPERIMENTAL
Intervention: Fallopian tube tissue specimens from infertile women with chronic salpingitis and/or salpingitis isthmica nodosa
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control group (28 fertile women)
Number of subjects: 56
Study: 8600589

Group type: EXPERIMENTAL
Intervention: Live attenuated varicella vaccine (Oka strain) with a mean virus titre of 10(4,5) PFUs per dose
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Live attenuated varicella vaccine (Oka strain) with a mean virus titre of 10(3,1) PFUs per dose
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Live attenuated varicella vaccine (Oka strain) with a mean virus titre of 10(3,9) PFUs per dose
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Live attenuated varicella vaccine (Oka strain) with a mean virus titre of 10(2,7) PFUs per dose
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Live attenuated varicella vaccine (Oka strain)
Number of subjects: 200
Study: 2529543

Group type: EXPERIMENTAL
Intervention: Acetorphan (oral administration)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 8
Study: 361345

Group type: EXPERIMENTAL
Intervention: Loxapine (average maximum daily dose: 60.0 mg)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Perphenazine (average daily dosage: 36.8 mg)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Loxapine (average daily dosage: 81.1 mg)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Perphenazine (average daily dosage: 90.1 mg)
Number of subjects: 47
Study: 31257404

Group type: EXPERIMENTAL
Intervention: α1 microglobulin (α1m)
Number of subjects: 2377

Group type: EXPERIMENTAL
Intervention: β2 microglobulin (β2m)
Number of subjects: 2377

Group type: EXPERIMENTAL
Intervention: Uromodulin
Number of subjects: 2377
Study: 27995369

Group type: EXPERIMENTAL
Intervention: Oral analgesics (paracetamol, ibuprofen, or a combination)
Number of subjects: 884

Group type: EXPERIMENTAL
Intervention: Bodily Pain Score of the SF-36
Number of subjects: 884
Study: 25796191

Group type: EXPERIMENTAL
Intervention: High-density genetic map construction using 1712 SSR primer pairs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Morphological markers identified
Number of subjects: 0
Study: 23786776

Group type: EXPERIMENTAL
Intervention: Tamoxifen 10 mg/week
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg/day
Number of subjects: 125

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 125
Study: 21698928

Group type: EXPERIMENTAL
Intervention: Individualized surgical tactics
Number of subjects: 210

Group type: COMPARATOR
Intervention: Conventional surgical approaches
Number of subjects: 210
Study: 19175639

Group type: EXPERIMENTAL
Intervention: Defunctioning stoma (DS)
Number of subjects: 4417

Group type: COMPARATOR
Intervention: No defunctioning stoma (without DS)
Number of subjects: 4417
Study: 17034438

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral relapse prevention support group
Number of subjects: 291

Group type: EXPERIMENTAL
Intervention: Individualized brief motivational enhancement
Number of subjects: 291

Group type: COMPARATOR
Intervention: Delayed treatment control group
Number of subjects: 291
Study: 15222971

Group type: EXPERIMENTAL
Intervention: Healthy participants with no interruption
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Healthy participants interrupted early
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Healthy participants interrupted late
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Healthy participants interrupted both early and late
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Dysexecutive patients
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Age-matched controls
Number of subjects: 101
Study: 11206598

Group type: EXPERIMENTAL
Intervention: Once-weekly fluoxetine
Number of subjects: 109

Group type: COMPARATOR
Intervention: Once-daily fluoxetine
Number of subjects: 109
Study: 9493921

Group type: EXPERIMENTAL
Intervention: Laboratory polysomnographic (LPSG) monitoring
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Home polysomnographic (HPSG) monitoring
Number of subjects: 64
Study: 7691017

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 35

Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 35
Study: 3705820

Group type: EXPERIMENTAL
Intervention: Tranquilizers, antidepressants, neuroleptics, nootropic drugs, and rational psychotherapy
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Experimental and psychological examination
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Clinical follow-up
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Computer-aided tomography
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Electroencephalo-, rheoencephalo- and echoencephalography
Number of subjects: 138
Study: 30524424

Group type: EXPERIMENTAL
Intervention: Oral Immunotherapy (OIT) for peanut allergy
Number of subjects: 21
Study: 27367877

Group type: EXPERIMENTAL
Intervention: 12-month intervention (n=148) including PCP and patient training, case management by trained nurses, and clinical decision support for PCPs.
Number of subjects: 291

Group type: COMPARATOR
Intervention: Usual care (n=143) provided by primary care physician including periodic contacts, referrals to specialists, and prescription of medication.
Number of subjects: 291
Study: 24381088

Group type: EXPERIMENTAL
Intervention: Blood pressure (BP) cuff inflated during the first 75 s of recovery period to prolong muscle ischemia
Number of subjects: 16

Group type: COMPARATOR
Intervention: No intervention (baseline measures)
Number of subjects: 16
Study: 22005648

Group type: EXPERIMENTAL
Intervention: Donor-derived CD3(+) cell count (ddCD3) <110/μL at 8 weeks post-transplantation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Higher ddCD3 at 8 weeks post-transplantation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Higher ddCD3 when partially chimeric
Number of subjects: 0
Study: 20881958

Group type: EXPERIMENTAL
Intervention: etravirine
Number of subjects: 577

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 577
Study: 18541128

Group type: EXPERIMENTAL
Intervention: Test formulation: ibuprofen (400 mg capsule)
Number of subjects: 24
Study: 15908741

Group type: EXPERIMENTAL
Intervention: Basiliximab
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control
Number of subjects: 100
Study: 12135217

Group type: EXPERIMENTAL
Intervention: Saline infusion hysterosonography
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Hysteroscopy
Number of subjects: 117

Group type: COMPARATOR
Intervention: Both procedures
Number of subjects: 117
Study: 10374704

Group type: EXPERIMENTAL
Intervention: Heparin plus aspirin (single therapy)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Complete therapy (lymphocyte immunizations, heparin, and aspirin)
Number of subjects: 19
Study: 7487614

Group type: EXPERIMENTAL
Intervention: Immediate pars plana vitrectomy (VIT)
Number of subjects: 420

Group type: COMPARATOR
Intervention: Vitreous tap or biopsy (TAP)
Number of subjects: 420

Group type: COMPARATOR
Intervention: Systemic antibiotics (ceftazidime and amikacin)
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: No systemic antibiotics
Number of subjects: 420
Study: 2299370

Group type: EXPERIMENTAL
Intervention: Low-dose cytarabine (LD ARA‐C) 20 mg/m2 for 21 days
Number of subjects: 87

Group type: COMPARATOR
Intervention: Intensive chemotherapy (rubidazone 100 mg/m2 for 4 days, ARA‐C 200 mg/m2 for 7 days)
Number of subjects: 87
Study: 6788069

Group type: EXPERIMENTAL
Intervention: 2% sodium cromoglycate eyedrops, 4 times a day
Number of subjects: 17

Group type: COMPARATOR
Intervention: 2% sodium cromoglycate eyedrops
Number of subjects: 17
Study: 29159870

Group type: EXPERIMENTAL
Intervention: Predictive hyperglycemia and hypoglycemia minimization (PHHM) system
Number of subjects: 28

Group type: COMPARATOR
Intervention: Predictive low glucose suspension (PLGS) alone
Number of subjects: 28
Study: 26619790

Group type: EXPERIMENTAL
Intervention: Yogurt with 6 g inulin (YI)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Yogurt without inulin (YC)
Number of subjects: 19
Study: 25366680

Group type: EXPERIMENTAL
Intervention: Accelerated fractionation with concomitant boost (AFX-C)
Number of subjects: 721

Group type: COMPARATOR
Intervention: Standard fractionation (SFX)
Number of subjects: 721

Group type: EXPERIMENTAL
Intervention: p16-positive patients
Number of subjects: 721

Group type: COMPARATOR
Intervention: p16-negative patients
Number of subjects: 721
Study: 23106890

Group type: EXPERIMENTAL
Intervention: Losartan 150 mg daily
Number of subjects: 545

Group type: COMPARATOR
Intervention: Losartan 50 mg daily
Number of subjects: 545
Study: 20335449

Group type: EXPERIMENTAL
Intervention: Exercise (home-based stationary cycling program from 20 wk gestation to delivery)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Control (no exercise)
Number of subjects: 84
Study: 18586132

Group type: EXPERIMENTAL
Intervention: Supervised exercise program
Number of subjects: 60

Group type: COMPARATOR
Intervention: Exercise advice
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Long-term follow-up
Number of subjects: 60
Study: 15941825

Group type: COMPARATOR
Intervention: Nasal mask
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Nasal prong
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Nasal device used (mask or prong)
Number of subjects: 89
Study: 11836166

Group type: EXPERIMENTAL
Intervention: Cytogenetic analysis at diagnosis
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: t(9;22) chromosomal rearrangement
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Slow response to therapy (assessed by percentage of blast cells higher than 10% in bone marrow study on day 14)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Slow response to therapy (assessed by presence of blast cells in peripheral blood on day 8)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Cytogenetic study results
Number of subjects: 130
Study: 10480703

Group type: EXPERIMENTAL
Intervention: Sensitivity to any individual allergens tested
Number of subjects: 1816

Group type: EXPERIMENTAL
Intervention: Atopy
Number of subjects: 1816

Group type: EXPERIMENTAL
Intervention: Atopy in symptomatic individuals
Number of subjects: 1816
Study: 8707777

Group type: EXPERIMENTAL
Intervention: Asthmatic children (n=36)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Normal controls (n=36)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Asthmatic children (n=10)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Normal controls (n=10)
Number of subjects: 92
Study: 1986564

Group type: EXPERIMENTAL
Intervention: Enalapril, titrated to reduce mean arterial pressure by 10 mm Hg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Isocaloric 0.8 g/kg protein diet
Number of subjects: 12
Study: 6406156

Group type: EXPERIMENTAL
Intervention: Dimotapp
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control
Number of subjects: 24
Study: 31126281

Group type: EXPERIMENTAL
Intervention: Ongoing real-life longitudinal study of difficult asthma
Number of subjects: 0
Study: 29878445

Group type: EXPERIMENTAL
Intervention: Supervised resistance training once-a-week for 9 months
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Supervised resistance training twice-a-week for 9 months
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Supervised resistance training three-times-a-week for 9 months
Number of subjects: 106

Group type: COMPARATOR
Intervention: Non-training control group
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Resistance training intervention
Number of subjects: 106
Study: 27498129

Group type: EXPERIMENTAL
Intervention: FEC-T plus pertuzumab
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: PTC plus pertuzumab
Number of subjects: 110
Study: 25997778

Group type: EXPERIMENTAL
Intervention: HIGH (2 × 10‐15 repetitions at 80% of 1RM)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: LOW (1 × 80‐100 repetitions at 20% of 1RM)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: LOW+ (1 × 60 repetitions at 20% of 1RM + 1 × 10‐20 repetitions at 40% 1RM)
Number of subjects: 56
Study: 22669350

Group type: EXPERIMENTAL
Intervention: Single vision lenses
Number of subjects: 92
Study: 20887414

Group type: EXPERIMENTAL
Intervention: 10 mg melatonin
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 18541827

Group type: EXPERIMENTAL
Intervention: Topiramate (up to 300 mg/d)
Number of subjects: 371
Study: 16000281

Group type: EXPERIMENTAL
Intervention: 18F‐FCWAY (5‐HT 1A receptor antagonist)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Beck Depression Inventory Scale
Number of subjects: 22
Study: 12413702

Group type: EXPERIMENTAL
Intervention: Qatoor Ramad (QR) eye drops, 2 drops (3-4 times/day) for up to 14 days
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo (not explicitly mentioned in the abstract)
Number of subjects: 70
Study: 10621951

Group type: EXPERIMENTAL
Intervention: Sumatriptan (100 mg orally)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Subsequent treatment with serotonin specific reuptake inhibitors (SSRIs)
Number of subjects: 14
Study: 7860745

Group type: EXPERIMENTAL
Intervention: 600 mg/d cholesterol with high saturated fat
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: 600 mg/d cholesterol with increased polyunsaturated fat
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: 200 mg/d cholesterol with high saturated fat
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: 200 mg/d cholesterol with low saturated fat
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: 600 mg/d cholesterol with low saturated fat
Number of subjects: 84
Study: 1955161

Group type: EXPERIMENTAL
Intervention: Adrenaline injection (1:10,000)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Adrenaline injection + Nd:YAG laser photocoagulation
Number of subjects: 42
Study: 6135908

Group type: EXPERIMENTAL
Intervention: ICI 118630 (100 micrograms daily)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: ICI 118630 (250 micrograms daily)
Number of subjects: 8
Study: 30811282

Group type: EXPERIMENTAL
Intervention: Enzalutamide and Leuprolide with Abiraterone and Prednisone (ELAP)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Enzalutamide and Leuprolide (EL)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Both ELAP and EL
Number of subjects: 75
Study: 28672094

Group type: EXPERIMENTAL
Intervention: nHFOV
Number of subjects: 81

Group type: COMPARATOR
Intervention: nCPAP
Number of subjects: 81
Study: 27548711

Group type: EXPERIMENTAL
Intervention: Experimental Diet (ED)
Number of subjects: 17